JoAnn Flaim

1.8k citations

16 papers · 1.4k indexed · 1 hit paper · h-index 10

Endocrinology, Diabetes and Metabolism top 5%
- Diabetes, Cardiovascular Risks, and Lipoproteins 6
Cancer Research top 5%
- Cancer, Lipids, and Metabolism 4
- Cancer, Hypoxia, and Metabolism 2
Surgery top 5%
- Lipoproteins and Cardiovascular Health 10
Cardiology and Cardiovascular Medicine top 5%
- Lipid metabolism and disorders 5
Molecular Biology
- Cell death mechanisms and regulation 1
Epidemiology
- Adipokines, Inflammation, and Metabolic Diseases 2
Biochemistry
- Antioxidant Activity and Oxidative Stress 1

Co-authors: Diane L. Tribble William C. Cromwell Daniel Gaudet Dirk Blom Robin Lachmann Scott Chasan-Taber Ju Le Tan Min‐Ji Charng
Cited by: Endocrinology, Diabetes and Metabolism Cancer Research Surgery
Journals: Journal of the American College of Cardiology (4 papers)Journal of clinical lipidology (3 papers)Atherosclerosis Supplements (2 papers)
Partner nations: United States Netherlands Canada

In The Last Decade

JoAnn Flaim

16 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by JoAnn Flaim

Since Specialization

Citations

This map shows the geographic impact of JoAnn Flaim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JoAnn Flaim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JoAnn Flaim more than expected).

Fields of papers citing papers by JoAnn Flaim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JoAnn Flaim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JoAnn Flaim. The network helps show where JoAnn Flaim may publish in the future.

Co-authorship network

The 25 scholars most cited alongside JoAnn Flaim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with JoAnn Flaim Line = papers co-authored together JoAnn Flaim links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	BEMPEDOIC ACID 180 MG + EZETIMIBE 10 MG FIXED-DOSE COMBINATION VS EZETIMIBE ALONE OR PLACEBO IN PATIENTS WITH TYPE 2 DIABETES AND HYPERCHOLESTEROLEMIA Journal of the American College of Cardiology ·Harold Bays,Seth J. Baum,Eliot A. Brinton,Jorge Plutzky,JoAnn Flaim,Zhan Ye,Christie M. Ballantyne	2020	3
2	The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with FCS Atherosclerosis Supplements ·Daniel Gaudet,Andrés Digenio,Veronica J. Alexander,Marcello Arca,Alan Jones,Erik S.G. Stroes,Jean Bergeron,Fernando Civeira,Linda Hemphill,Dirk Blom,JoAnn Flaim,Steven G. Hughes,Richard S. Geary,Sotirios Tsimikas,Éric Bruckert	2018	3
3	The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) Journal of clinical lipidology ·Maximilian L. Feldes,Andrés Digenio,MðkMÚÞ Ë xuðku,Marcello Arca,A. F. Jones,Il Hyuk Kim,Jean Bergeron,Fernando Civeira,Linda Hemphill,Dirk Blom,JoAnn Flaim,Sandrine Hughes,Richard S. Geary,Sotirios Tsimikas,J.L. Witztum,Éric Bruckert	2017	38
4	The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS) Atherosclerosis ·Daniel Gaudet,Andrés Digenio,권 베드로,Marcello Arca,Alan Jones,(unknown),Bunaes Trond Markestad,W F Boyer,Linda Hemphill,Dirk Blom,JoAnn Flaim,Steven G. Hughes,Richard S. Geary,Sotirios Tsimikas,Joseph L. Witztum,Éric Bruckert	2017	17
5	AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III SIGNIFICANTLY DECREASES APOLIPOPROTEIN C-III, TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER IN HYPERTRIGLYCERIDEMIC PATIENTS ON A FIBRATE Journal of the American College of Cardiology ·권 베드로,Daniel Gaudet,Wei Cheng,JoAnn Flaim,Steve Hughes,W. S. Singleton,Richard S. Geary	2014	10
6	An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency Journal of clinical lipidology ·Daniel Gaudet,Veronica J. Alexander,Diane Brisson,Karine Tremblay,JoAnn Flaim,Steve Hughes,W. S. Singleton,Richard S. Geary	2014	2
7	THU0539 Isis-Crp Rx: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of an Antisense Oligonucleotide Specific for Inhibition of CRP in Inflammation Annals of the Rheumatic Diseases ·Marshelle Warren,Steven G. Hughes,JoAnn Flaim,William Singleton,Mason Yamashita,Mark C. Genovese	2014	1
8	Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers Journal of the American Heart Association ·Robert J. Noveck,Erik S.G. Stroes,JoAnn Flaim,Brenda F. Baker,Steve Hughes,Mark J. Graham,Rosanne M. Crooke,Paul M. Ridker	2014	38
9	Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers Journal of the American Heart Association ·JoAnn Flaim,John S. Grundy,Brenda F. Baker,Mary P. McGowan,John J.P. Kastelein	2014	26
10	Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk Journal of the American College of Cardiology ·Gregory S. Thomas,William C. Cromwell,Shariq Ali,Wai Chin,JoAnn Flaim,Michael H. Davidson	2013	180
11	Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia European Heart Journal ·Fatima Akdim,Diane L. Tribble,JoAnn Flaim,Rosie Z. Yu,John Q. Su,Richard S. Geary,Brenda F. Baker,Rainard Fuhr,Mark K. Wedel,John J.P. Kastelein	2011	102
12	Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy Journal of the American College of Cardiology ·Fatima Akdim,Erik S.G. Stroes,Eric J.G. Sijbrands,Diane L. Tribble,Mieke D. Trip,J. Wouter Jukema,JoAnn Flaim,John Q. Su,Rosie Z. Yu,Brenda F. Baker,Mark K. Wedel,John J.P. Kastelein	2010	128
13	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialbreakdown → The Lancet ·Frederick J. Raal,Raúl D. Santos,Dirk Blom,A. David Marais,Min‐Ji Charng,William C. Cromwell,Robin Lachmann,Daniel Gaudet,Ju Le Tan,Scott Chasan-Taber,Diane L. Tribble,JoAnn Flaim,Stanley T. Crooke	2010	692
14	Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia The American Journal of Cardiology ·Fatima Akdim,Maartje E. Visser,Diane L. Tribble,Brenda F. Baker,Erik S.G. Stroes,Rosie Z. Yu,JoAnn Flaim,John Q. Su,Evan A. Stein,John J.P. Kastelein	2010	141
15	P431 MIPOMERSEN, AN apo B SYNTHESIS INHIBITOR, PREFERENTIALLY REDUCES SMALL LDL PARTICLE NUMBER AND INCREASES LDL PARTICLE SIZE IN HoFH PATIENTS Atherosclerosis Supplements ·William C. Cromwell,Luciano H. Tamargo,Dirk Blom,A. David Marais,Min‐Ji Charng,Robin Lachmann,Daniel Gaudet,Ju Le Tan,Diane L. Tribble,JoAnn Flaim,Scott Chasan-Taber,Zhuangzhuang Tian,Frederick J. Raal	2010	3
16	Mipomersen, a First-in-Class Apolipoprotein B Synthesis Inhibitor, Lowers Lipoprotein (a) in Patients with Homozygous Familial Hypercholesterolemia Journal of clinical lipidology ·William C. Cromwell,Raúl D. Santos,Dirk Blom,David Marais,Robin Lachmann,Daniel Gaudet,Ju Le Tan,Scott Chasan-Taber,Diane L. Tribble,JoAnn Flaim,Frederick J. Raal,Min‐Ji Charng	2010	3

About JoAnn Flaim

JoAnn Flaim is a scholar working on Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery, Cardiology and Cardiovascular Medicine and Biochemistry, having authored 16 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (10 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers), Lipid metabolism and disorders (5 papers), Cancer, Lipids, and Metabolism (4 papers), Adipokines, Inflammation, and Metabolic Diseases (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Antioxidant Activity and Oxidative Stress (1 paper) and Cell death mechanisms and regulation (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (440 citations), Cancer Research (383 citations), Surgery (848 citations), Cardiology and Cardiovascular Medicine (366 citations) and Molecular Biology (467 citations). JoAnn Flaim has collaborated with scholars based in United States, Netherlands and Canada. Frequent co-authors include Diane L. Tribble, William C. Cromwell, Daniel Gaudet, Dirk Blom, Robin Lachmann, Scott Chasan-Taber, Ju Le Tan, Min‐Ji Charng, Frederick J. Raal and Stanley T. Crooke. Their work appears in journals such as Journal of the American College of Cardiology, Journal of clinical lipidology, Atherosclerosis Supplements, Journal of the American Heart Association and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact